Compare Stocks: GSK, AZN, BMK, and DPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$166.65 +2.9%	$161.96	$153.41 ▼ $212.71	$258.46B	0.27	2.81 million shs	4.40 million shs
BMK MacDonald Mines Exploration	C$0.09 -10.5%	C$0.08	C$0.03 ▼ C$0.10	C$3.24M	0.15	67,505 shs	26,780 shs
GSK GSK	$49.06 +2.5%	$49.74	$42.85 ▼ $61.69	$99.23B	0.33	4.49 million shs	6.14 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+4.02%	+1.26%	-0.95%	-4.07%	-4.72%
BMK MacDonald Mines Exploration	0.00%	0.00%	0.00%	0.00%	0.00%
GSK GSK	+3.64%	+1.95%	-4.29%	-9.19%	+8.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$166.65 +2.9%	$161.96	$153.41 ▼ $212.71	$258.46B	0.27	2.81 million shs	4.40 million shs
BMK MacDonald Mines Exploration	C$0.09 -10.5%	C$0.08	C$0.03 ▼ C$0.10	C$3.24M	0.15	67,505 shs	26,780 shs
GSK GSK	$49.06 +2.5%	$49.74	$42.85 ▼ $61.69	$99.23B	0.33	4.49 million shs	6.14 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+4.02%	+1.26%	-0.95%	-4.07%	-4.72%
BMK MacDonald Mines Exploration	0.00%	0.00%	0.00%	0.00%	0.00%
GSK GSK	+3.64%	+1.95%	-4.29%	-9.19%	+8.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.79	Moderate Buy	$206.67	24.01% Upside
BMK MacDonald Mines Exploration	0.00	N/A	N/A	N/A
GSK GSK	2.05	Hold	$55.33	12.79% Upside

Current Analyst Ratings Breakdown

Latest GSK, AZN, BMK, and DPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	AZN Astrazeneca	Nordea Equity Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell ➝ Buy
10/13/2026	AZN Astrazeneca	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/9/2026	GSK GSK	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$70.00
10/6/2026	AZN Astrazeneca	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/6/2026	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/1/2026	GSK GSK	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell
9/29/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/28/2026	GSK GSK	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/15/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell ➝ Hold
9/15/2026	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$60.00
9/15/2026	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$54.00 ➝ $60.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$58.74B	4.40	$13.83 per share	12.05	$31.41 per share	5.31
BMK MacDonald Mines Exploration	-C$74K	-43.74	C$0.01 per share	13.00	C($0.02) per share	-4.25
GSK GSK	$33.20B	2.99	$6.36 per share	7.71	$10.32 per share	4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.69	24.91	15.81	1.32	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
BMK MacDonald Mines Exploration	-C$1.28M	N/A	N/A	N/A	N/A	N/A	-1,679.48%	-118.05%	N/A
GSK GSK	$7.54B	$3.20	15.34	9.81	2.08	14.56%	43.23%	11.60%	10/28/2026 (Estimated)

Latest GSK, AZN, BMK, and DPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2026	Q3 2026	AZN Astrazeneca	$2.60	N/A	N/A	N/A	$16.04 billion	N/A
10/28/2026	Q3 2026	GSK GSK	$1.33	N/A	N/A	N/A	$11.73 billion	N/A
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$1.61	$15.44 billion	$15.38 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.60%	+2.30%	64.87%	N/A
BMK MacDonald Mines Exploration	N/A	1.24%	N/A	N/A	N/A
GSK GSK	$1.77	3.61%	-7.86%	55.31%	N/A

Latest BMK, AZN, GSK, and DPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.47	0.89	0.67
BMK MacDonald Mines Exploration	3.84	0.10	0.27
GSK GSK	0.81	0.82	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
BMK MacDonald Mines Exploration	N/A
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
BMK MacDonald Mines Exploration	6.86%
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
BMK MacDonald Mines Exploration	2	38.08 million	N/A	Not Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable

GSK, AZN, BMK, and DPH Headlines

Recent News About These Companies

Global Restructuring And US Biologics Bet Could Be A Game Changer For GSK (LSE:GSK)

October 14 at 12:25 AM | finance.yahoo.com

28,800 Shares in GSK PLC Sponsored ADR $GSK Purchased by Sanders Morris Harris LLC

October 14 at 7:05 PM | marketbeat.com

GSK (NYSE:GSK) Stock Jumps 3.5% - Here's Why

October 14 at 2:39 PM | marketbeat.com

GSK planning 1,200 job cuts in Belgium, says paper

October 14 at 2:24 PM | pharmaphorum.comP

GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam

October 14 at 2:24 PM | fiercebiotech.comF

GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan

October 14 at 2:24 PM | msn.com

First Patient Dosed in GSK-Oxford Colitis Trial

October 14 at 9:24 AM | miragenews.comM

Market Chatter: GSK Plans Up to 1,217 Job Cuts in Belgium

October 14 at 9:24 AM | finance.yahoo.com

Over 1,200 jobs under threat at vaccine manufacturer GSK

October 14 at 9:24 AM | vrt.beV

Pharmaceutical giant GSK to eliminate 1,200 jobs in Belgium

October 14 at 9:24 AM | brusselstimes.comB

GSK plans more than 1,200 job cuts in Belgium

October 14 at 9:24 AM | msn.com

GSK to cut up to 1,217 jobs in Belgium

October 14 at 9:24 AM | msn.com

GSK to cut up to 1,217 jobs in Belgium, L'Echo says

October 14 at 4:51 AM | reuters.com

GSK to invest $800M in Pennsylvania expansion

October 13 at 1:39 PM | finance.yahoo.com

GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength

October 13 at 8:38 AM | proactiveinvestors.com

Contrasting GSK (NYSE:GSK) and United-Guardian (NASDAQ:UG)

October 13 at 8:17 AM | americanbankingnews.com

GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength

October 13 at 5:41 AM | proactiveinvestors.com

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

October 12 at 2:33 PM | etftrends.comE

GSK to demolish, rebuild on River Road for $800 million Upper Merion factory

October 12 at 2:13 PM | msn.com

Is the Options Market Predicting a Spike in GSK Plc Stock?

October 12 at 2:13 PM | finance.yahoo.com

Is the Options Market Predicting a Spike in GSK Plc Stock?

October 12 at 12:41 PM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, BMK, and DPH Company Descriptions

Astrazeneca NYSE:AZN

$166.65 +4.62 (+2.85%)

Closing price 03:59 PM Eastern

Extended Trading

$168.16 +1.50 (+0.90%)

As of 07:02 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

MacDonald Mines Exploration CVE:BMK

C$0.08 -0.01 (-10.53%)

As of 05/6/2025

MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company primarily explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interests in the Scadding-Powerline-Jovan project that covers an area of 19,455 hectares located in the southeast of the prolific Sudbury Mining Camp in Northern Ontario; and the Hembruff Copper Property, which consists of 30 mining claims that covers an area of 6.64 square kilometers situated in the Elliot Lake, Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was founded in 1935 and is based in Toronto, Canada.

GSK NYSE:GSK

$49.06 +1.19 (+2.48%)

Closing price 03:59 PM Eastern

Extended Trading

$49.57 +0.51 (+1.04%)

As of 06:51 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GSK, AZN, BMK, and DPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GSK, AZN, BMK, and DPH Earnings

Compare Dividends

Latest BMK, AZN, GSK, and DPH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GSK, AZN, BMK, and DPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, BMK, and DPH Company Descriptions

Astrazeneca NYSE:AZN

MacDonald Mines Exploration CVE:BMK

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GSK, AZN, BMK, and DPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GSK, AZN, BMK, and DPH Earnings

Compare Dividends

Latest BMK, AZN, GSK, and DPH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GSK, AZN, BMK, and DPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, BMK, and DPH Company Descriptions

Astrazeneca NYSE:AZN

MacDonald Mines Exploration CVE:BMK

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools